Sanofi (SNY +0.8%) reported positive results for its MS drug Lemtrada late yesterday, saying it...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi (SNY +0.8%) reported positive results for its MS drug Lemtrada late yesterday, saying it remained effective during the first year of an extension study. The data "really speaks to Lemtrada's unique approach to disease modification," says the company's Michael Panzara, speaking at a Neurology conference. An under-the-radar way to play Lemtrada's success is discussed in this SA Pro article.